Disc Medicine Inc

IRON remains in a Stage 2 advancing corrective reset within its long-term uptrend. Medium-term bias is bullish as price holds above rising EMAs and the 50-day MA despite the recent overbought corrective pullback. Short-term timing is neutral with price pulling back into the EMA band without clear acceptance or reversal signals. Given the speculative strategy, engagement should be deferred and monitored around the rising EMAs and mid-70s support zone.

• ↑Avg analyst price target $101.50 implies 39% upside potential.
• ↑33% share gain over past year shows strong momentum.
• ↓Q1 EPS -$1.65 with zero revenue highlights severe cash burn.